Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuaki Shindoh

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|April 18, 2008
Histone deacetylase inhibitors from microorganisms: the Astellas experienceYuhta Masuoka, Nobuaki Shindoh, Noriaki Inamura
Scientific Reports|October 12, 2019
Identification of a novel oncogenic mutation of FGFR4 in gastric cancerTakashi Futami, Tatsuya Kawase, Kenichi Mori, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus XestospongiaNaoya Oku, Koji Nagai, Nobuaki Shindoh, et al.
Molecular Cancer Therapeutics|November 13, 2016
ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular CarcinomaTakashi Futami, Hidetsugu Okada, Rumi Kihara, et al.
Cancer Science|November 26, 2016
ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistanceAya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, et al.
Plos One|November 13, 2012
Next-generation cDNA screening for oncogene and resistance phenotypesNobuaki Shindoh, Akinori Yoda, Yuka Yoda, et al.
International Journal of Oncology|February 23, 2008
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft modelNobuaki Shindoh, Masamichi Mori, Yoh Terada, et al.
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|April 18, 2008
Histone deacetylase inhibitors from microorganisms: the Astellas experienceYuhta Masuoka, Nobuaki Shindoh, Noriaki Inamura
Scientific Reports|October 12, 2019
Identification of a novel oncogenic mutation of FGFR4 in gastric cancerTakashi Futami, Tatsuya Kawase, Kenichi Mori, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus XestospongiaNaoya Oku, Koji Nagai, Nobuaki Shindoh, et al.
Molecular Cancer Therapeutics|November 13, 2016
ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular CarcinomaTakashi Futami, Hidetsugu Okada, Rumi Kihara, et al.
Cancer Science|November 26, 2016
ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistanceAya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, et al.
Plos One|November 13, 2012
Next-generation cDNA screening for oncogene and resistance phenotypesNobuaki Shindoh, Akinori Yoda, Yuka Yoda, et al.
International Journal of Oncology|February 23, 2008
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft modelNobuaki Shindoh, Masamichi Mori, Yoh Terada, et al.
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
Pageof 1